# CAR-PRISM (NCT05767359)

> CAR- PRISM (PRecision Intervention Smoldering Myeloma)

No report yet. It can be ordered.

- Drugs tested: ciltacabtagene autoleucel
- Indication: high-risk smoldering multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05767359
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Multiple Myeloma; Smoldering Multiple Myeloma
- Interventions: Ciltacabtagene Autoleucel; Cyclophosphamide; Fludarabine Phosphate
- Enrollment: 20
- Primary outcome: Incidence of Dose Limiting Toxicities (DLT)
- Primary outcome: Nature of Dose Limiting Toxicities (DLT)
- Primary outcome: Incidence of Adverse Events (AEs)

## Indexed commentary on CAR-PRISM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 25
- YouTube: 16
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=car-prism-nct05767359

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05767359", "email": "<work email>"}; the inbox owner confirms by the emailed link.